Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Chubb
Boehringer Ingelheim
Deloitte
Medtronic
Harvard Business School
Dow
Argus Health
Mallinckrodt

Generated: April 24, 2018

DrugPatentWatch Database Preview

Details for Patent: RE44733

« Back to Dashboard

Which drugs does patent RE44733 protect, and when does it expire?

Patent RE44733 protects BRIDION and is included in one NDA.

This patent has thirty-nine patent family members in twenty-nine countries.
Summary for Patent: RE44733
Title:6-mercapto-cyclodextrin derivatives:reversal agents for drug-induced neuromuscular block
Abstract: Disclosed is a 6-mercapto-cyclodextrin derivative having general formula (I) wherein m is 0-7 and n is 1-8 and m+n=7 or 8; R is (C.sub.1-6)alkylene, optionally substituated with 1-3 OH groups, or (CH.sub.2).sub.o-phenylene-(CH.sub.2).sub.p--; o and p are independently 0-4; X is COOH, CONHR.sub.1, NHCOR.sub.2, SO.sub.2OH, PO(OH).sub.2, O(CH.sub.2--CH.sub.2--O).sub.q--H, OH or tetrazol-5-yl; R.sub.1 is H or (C.sub.1-3)alkyl; R.sub.2 is carboxyphenyl; q is 1-3; or pharmaceutically acceptable salts thereof. The 6-mercaptocyclodextrin derivative is highly suitable for use in the reversal of drug-induced neuromuscular block. ##STR00001##
Inventor(s): Zhang; Mingiang (Montreal, CA), Palin; Ronald (Banton, GB), Bennett; Jonathan (Edinburgh, GB)
Assignee: Merck Sharp & Dohme B.V. (Haarlem, NL)
Application Number:13/432,742
Patent Claim Types:
see list of patent claims
Compound; Composition; Device; Use;

Drugs Protected by US Patent RE44733

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Organon Sub Merck BRIDION sugammadex sodium SOLUTION;INTRAVENOUS 022225-002 Dec 15, 2015 RX Yes No ➤ Sign Up ➤ Sign Up Y Y REVERSAL OF DRUG-INDUCED NEUROMUSCULAR BLOCK ➤ Sign Up
Organon Sub Merck BRIDION sugammadex sodium SOLUTION;INTRAVENOUS 022225-001 Dec 15, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y REVERSAL OF DRUG-INDUCED NEUROMUSCULAR BLOCK ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: RE44733

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
99309558Nov 29, 1999
PCT Information
PCT FiledNovember 23, 2000PCT Application Number:PCT/EP00/11789
PCT Publication Date:June 07, 2001PCT Publication Number: WO01/40316

Non-Orange Book US Patents Family Members for Patent RE44733

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,670,340 6-Mercapto-cyclodextrin derivatives:reversal agents for drug-induced neuromuscular block ➤ Sign Up
6,949,527 6-Mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Accenture
Chinese Patent Office
McKesson
US Army
Merck
Argus Health
Baxter
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.